The combination of erlotinib (ELT) and DHM can increase the expression of Bcl-2-interacting mediator of cell death (Bim) and induce NOX2-ROS-dependent caspase apoptosis in erlotinib-resistant NSCLC cells through the NOX2-ROS-Bim pathway [115]. Here, BCL2L11 is linked to non-small cell lung carcinoma.